SMALL MOLECULE APPROACH TO TREAT SYSTEMIC AA AMYLOIDOSIS DISEASE

 

ProteoTech is one of a few companies at the forefront of developing disease-modifying small molecule compounds targeted at inhibiting the formation and aggregation of toxic amyloid deposits found throughout the organs in patients with Systemic AA Amyloidosis disease.

 

This disease impacts in the United States alone, approximately 100,000 victims every year by attacking many of the human body's normal functioning organs with toxic amyloid deposits. The result of rapid amyloid deposition within multiple organs of these patients results in organ failure (kidney and/or heart) and eventual death within just a few years of the onset of the disease. There is no FDA approved treatment for this disease on the market today.

 

ProteoTech's lead small molecule, Systebryl^™ is currently in late pre-clinical stages of development and has shown to significantly prevent the formation and aggregation of toxic amyloid deposits associated with Systemic AA Amyloidosis disease. Research for this drug discovery and development program has been partially sponsored with funding from the National Institute of Health Small Business Innovation Research Grant (SBIR) award program from the National Institute of Arthritis and Musculoskeletal and Skin Diseases.

 

Due to the smaller population impacted by Systemic AA Amyloidosis, ProteoTech will request Orphan Drug Status from the FDA for its therapeutic compound in development of Systebryl^™. If granted, ProteoTech will enjoy market exclusivity and added patent protection for its proprietary technologies.